Limited sampling model for area under the concentration time curve of total topotecan

Clinical Cancer Research

Volumn 2, Issue 1, 1996, Pages 43-46

  Minami, Hironobu ^a   Beijnen, Jos H ^b   Verweij, Jaap ^c   Ratain, Mark J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

TOPOTECAN;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; HUMANS; MODELS, BIOLOGICAL; REGRESSION ANALYSIS; TOPOTECAN;

EID: 0030061851     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Kingsbury, W. D., Boehm, J. C., Jakas, D. R., Holden, K. G., Hecht, S. M., Gallagher, G., Caranfa, M. J., McCabe, F. L., Faucette, L. F., Johnson, R. K , and Hertzberg, R. P Synthesis of water soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J. Med. Chem., 34: 98-107, 1991.
2. Schiller, J. H., Kim, K., and Johnson, D. Phase II study of topotecan in extensive stage small cell lung cancer. Proc. Am. Soc, Clin. Oncol., 13: 330, 1994.
3. Ardizzoni, A., Hansen, H., Dombernowsky, P., Postmus, P., Buitenhuis, M., Wanders. J., McDonald, M , Giaccone, G., and Verweij, J. Phase II study of topotecan in pretreated small cell lung cancer. Proc. Am Soc. Clin. Oncol., 13: 336, 1994.
4. Perez-Soler, R., Glisson, B. S., Kane, J., Lee, J., Raber, M. N., and Hong, W. K. Phase II study of topotecan in patients with non-small cell lung cancer previously untreated. Proc. Am. Soc. Clin. Oncol., 13: 363, 1994.
5. Robert, F., Wheeler, R. H., Molthrop, D. C., Greene, P., and Chen, S. Phase II study of topotecan in advanced head and neck cancer: identification of an active new agent. Proc. Am. Soc. Clin. Oncol., 13: 281, 1994.
6. Kudelka, A., Edwards, C., Freedman, R., Wallin, B., Hord, M., Howell, E., Harper, K., Raber, M., and Kavanagh, J. An open phase II study to evaluate the efficacy and toxicity of topotecan administered intravenously as 5 daily infusions every 21 days to women with advanced epithelial ovarian carcinoma. Proc. Am. Soc. Clin. Oncol., 12: 259, 1993.
7. Eisenhauer, E. A., Wainman, N., Boos, G., Macdonald, D., and Bramwell, V. Phase II trial of topotecan in patients with malignant glioma and soft tissue sarcoma. Proc. Am. Soc. Clin. Oncol. 13: 175, 1994.
8. Miller, A. A., Hargis, J. B., Lilenbaum, R. C., Fields, S. Z., Rosner, G. L., and Schilsky, R. L. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a Cancer and Leukemia Group B study. J. Clin. Oncol., 12: 2743-2750, 1994.
9. Lilenbaum, R. C., Rosner, G. L., Ratain, M. J., Hargis, J. B., Miller, A. A., Green, M. R., and Schilsky, R. L. Phase I study of taxol and topotecan in patients with advanced solid tumors (CALGB 9362) Proc. Am. Soc. Clin. Oncol., 13: 131, 1994.
10. Eckardt, J. R., Burris, H. A., Rodriguez, G. A., Fields, S. M., Rothenbers, M. L., Moore, T. D., Smith, S. C., Ganapathi, R., Weiss, G. R., Johnson, R. K., Kuhn, J. G., and Von Hoff, D. D. A phase I study of the topoisomerase I and II inhibitors topotecan and etoposide. Proc. Am. Soc. Clin. Oncol., 12: 137, 1993.
11. Tolcher, A. W., O'Shaughnessy, J. A., Weiss, R. B., Myhand, R. C., Schneider, E., Hakim, F., Noone, M., Goldspiel, B., Kohler, D., and Cowan, K. H. A phase I study of topotecan (a topoisomerase I inhibitor) in combination with doxorubicin (a topoisomerase II inhibitor). Proc. Am. Soc. Clin. Oncol., 13: 157, 1994.
12. Houghton, P J., Cheshire, P. J., Myers, L., Stewart, C. F., Synold, T. W., and Houghton, J. A. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother. Pharmacol., 31: 229-239, 1992.
13. Rowinsky, E. K., Grochow, L. B., Hendricks, C. B , Ettinger, D. S., Forastiere, A. A., Hurowitz, L. A., McGuire, W. P., Sartorius, S. E., Lubejko, B. G., Kaufmann, S. H., and Donehower, R. C. Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor. J. Clin. Oncol., 10: 647-656, 1992.
14. Verweij, J., Lund, B., Beijnen, J., Planting, A., de Boer-Dennert, M., Koter, I., Rosing, H., and Hansen, H. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann. Oncol., 4: 673-678, 1993.
15. Saltz, L., Sirott, M., Young, C., Tong, W., Niedzwiecki, D., Tzy-Jyun, Y., Tao, Y., Trochanowski, B., Wright, P., Barbosa, K., Toomasi, F., and Kelsen, D. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J. Natl. Cancer Inst., 85: 1499-1507. 1993.
16. Haas, N. B., LaCreta, F. P., Walczak, J , Hudes, G. R., Brennan, J. M., Ozols, R. F., and O'Dwyer, P. J. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. Cancer Res., 54: 1220-1226, 1994.
17. Blaney, S. M., Balls, F. M., Cole, D. E., Craig, C., Reid, J. M., Ames, M. M., Krailo, M., Reaman, G., Hammond, D., and Poplack, D. G. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res., 53: 1032-1036, 1993.
18. Pratt, C. B., Stewart, C., Santana, V. M., Bowman, L., Furman, W., Ochs, J., Marina, N., Kuttesch, J. F., Heideman, R., Sandlund, J. T., Avery, L., and Meyer, W. H. Phase I study of topotecan for pediatric patients with malignant solid tumors. J. Clin. Oncol., 12: 539-543, 1994.
19. Hochster, H., Liebes, L., Speyer, J., Sorich, J., Taubes, B., Oratz, R., Wernz, J., Chachoua, A., Raphael, B., Vinci, R. Z., and Blum, R. H. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J. Clin. Oncol., 12: 553-559, 1994.
20. Stewart, C. F., Baker, S. D., Heideman, R. L., Jones, D., Crom, W. R., and Pratt, C. B. Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. J. Clin. Oncol., 12: 1946-1954, 1994.
21. van Warmerdam, L. J. C., Verweij, J., Schellens, J. H. M., Rosing, H., Davies, B. E., de Boer-Dennert, M., Maes, R. A. A., and Beijnen, J. H. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother. Pharmacol., 35: 237-245, 1995.
22. Grochow, L. B., Rowinsky, E. K., Johnson, R., Ludeman, S., Kaufmann, S. H., McCabe, F. L., Smith, B. R., Hurowitz, L., DeLisa, A., Donehower, R. C., and Noe, D. A. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab. Dispos., 20: 706-713, 1992.
23. Burke, T. G., Munshi, C. B., Mi, Z., and Jiang, Y. The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs. J. Pharm. Sci., 84: 518-519, 1995.
24. Beijnen, J. H., Smith, B. R., Keijer, W. J., van Gijn, R., ten Bokkel-Huinink, W. W., Vlasveld, L. T., Rodenhuis, S., and Underberg, W. J. M. High-performance liquid Chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma. J. Pharm. Biomed. Anal., 8: 789-794, 1990.
25. Rowinsky, E. K., Grochow, L. B., Ettinger, D. S., Sartorius, S. E., Lubejko, B. G., Chen, T-L . Rock, M. K., and Donehower, R. C. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res., 54: 427-436, 1994.
26. van Warmerdam, L. J C., Verweij, J., Rosing, H., Schellens, J. H. M., Maes, R. A. A., and Beijnen, J. H. Limited sampling models for topotecan pharmacokinetics, Ann. Oncol., 5: 259-264, 1994.
27. Sheiner, L. B., and Beal, S. L. Some suggestions for measuring predictive performance. J Pharmacokinet. Biopharm., 9: 503-512, 1981.
28. Ratain, M. J., and Vogelzang, N. J. Limited sampling model for vinblastine pharmacokinetics. Cancer Treat. Rep., 71: 935-939, 1987.
29. Ratain, M. J., Staubus, A. E., Schilsky, R. L., and Malspeis, L Limited sampling models for amonafide (NSC 308847) pharmacokinetics. Cancer Res., 48: 4127-4130, 1988.
30. Egorin, M. J., Forrest, A., Belani, C. P., Ratain, M. J., Abrams, J. S., and van Echo, D. A. A limited sampling strategy for cyclophosphamide pharmacokinetics Cancer Res., 49: 3129-3133, 1989.
31. Minami, H., Ando, Y., Sakai, S., and Shimokata, K. Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide. J. Chn. Oncol., 13: 191-199, 1995.